增骨协定方联合经皮椎体成形术治疗骨质疏松性椎体骨折48例

48 Cases Clinical Study on Zenggu Xieding Decoction Combined with Percutaneous Vertebro Plasty in Treating Osteoporotic Vertebral Compression Fracture

目的:观察增骨协定方联合经皮椎体成形术(PVP)治疗骨质疏松性椎体压缩性骨折(OVCF)的临床疗效和对患者血清骨代谢标志物的影响。方法:2017年4月至2020年2月收治的48例OVCF患者,在予以PVP术后,口服增骨协定方治疗6周,比较治疗前后患者胸腰背痛视觉模拟评分法(VAS)评分、功能指数(ODI)评分、骨代谢标志物血清骨钙素(BGP)及抗酒石酸酸性磷酸酶5b(TRACP-5b)的变化,记录不良事件及监测肝肾功能主要指标。结果:治疗后患者BGP水平较治疗前显著升高,差异有统计学意义(P<0.05);VAS评分、ODI评分和TRACP-5b水平下降,差异有统计学意义(P<0.05);肝肾功能主要指标治疗前后差异无统计学意义(P>0.05)。结论:增骨协定方联合经皮椎体成形术可以改善骨质疏松性椎体压缩性骨折症状及骨代谢,无明显肝肾损伤,值得临床推广应用。

Objective:To observe the efficacy of Zenggu Xieding decoction combined with percutaneous vertebro plasty(PVP)on the treatment of patients with osteoporotic lumbar vertebral compression fracture compression and serum markers of bone metabolism.Methods:48 patients with osteoporotic vertebral compression fracture from April 2017 to February 2020 were selected to receive Zenggu Xieding decoction treatment for 6 weeks after PVP.The changes of visual analogue scale(VAS),Oswestry disability index(ODI),bone mineral density(BMD)and the bone metabolic indicators:serum osteocalcin(BGP)and tartrate-resistant acid phosphatase isomer 5 b(TRACP-5 b)were recorded and compared before and after treatment.The adverse events were recorded and main indexes of liver and kidney function were monitored.The postoperative symptoms,functional recovery and bone metabolism improvement were evaluated.Results:The levels of BMD and BGP of patients after treatment were significantly higher than that before treatment(P<0.05);but the VAS score,ODI and TRACP-5 b level were significantly decreased(P<0.05).There was no significant difference in the main indexes of liver and kidney function before and after treatment(P>0.05).Conclusion:The PVP combine with Zenggu Xieding decoction can effectively improve the symbol of OVCF and promote bone metabolism without obvious liver and kidney damage,which is worthy of clinical promotion.